We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Delenex Therapeutics AG Expands Pipeline
Product News

Delenex Therapeutics AG Expands Pipeline

Delenex Therapeutics AG Expands Pipeline
Product News

Delenex Therapeutics AG Expands Pipeline

Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Delenex Therapeutics AG Expands Pipeline"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Delenex Therapeutics AG has announced that it has expanded its pipeline with two PENTRA®Bodies targeting interIeukin-17A and interleukin-1β.

Delenex has generated an anti-IL-17A PENTRA®Body for the treatment of dermatological and other inflammatory diseases. IL-17A is a pivotal interleukin which has been shown to play a key role in such medical conditions. Systemic administration of anti-IL-17A IgGs is an effective treatment of psoriasis, psoriatic arthritis and other diseases.

The small size of about 25 kDa of the PENTRA®Body and its extraordinary neutralizing potency (IC50) of ≤ 5 picomolar allow a unique positioning as compared to other anti-IL-17A treatments currently in clinical development.

Delenex’ lead candidate neutralizing IL-1β is a PENTRA®Body for the treatment of acne and other inflammatory diseases such as gouty arthritis. Delenex’ anti-IL-1β displays neutralizing potency in the femtomolar IC50 range (≤ 600 fM).

IL-1β has been shown to be over expressed in lesions of acne and to be a key mediator of skin inflammation in this disease that affects a substantial fraction of the population and demands innovative treatment modalities, especially in case of moderate-to-severe forms of acne.

In gout, the high potency and small size allow the application of this PENTRA®Body especially for the treatment of gout flares, where a fast onset and short action of the drug is required.

“The identification of such highly potent PENTRA®Bodies in a short period of time proves once again the power of our technology. PENTRA®Bodies are uniquely positioned vis-à-vis existing therapies and address the increasing demand for therapies that combine high potency with a favorable safety profile and cost-efficiency”, commented Titus Kretzschmar, PhD, Chief Scientific Officer at Delenex.